drugset / Trial / NCT04019002
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. If you chose to be in this study, you will be receiving novel magnetic resonance (MR) metabolic imaging with standard MR imaging. The research component includes an injection of an investigational agent, called hyperpolarized 13C pyruvate, to obtain dynamic metabolic imaging.
Timeline
- Start
- 2019-11-19
- Primary completion
- 2025-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized 13C-Pyruvate | Diagnostic / imaging agent | 0.43 unknown | Intravenous |